8,732 Shares in Humana Inc. (NYSE:HUM) Purchased by Bellwether Advisors LLC

Key Points

• Bellwether Advisors LLC has acquired a new position in Humana Inc., purchasing 8,732 shares valued at approximately $2.31 million in the first quarter.
• Humana reported an EPS of $11.58 for the last quarter, exceeding estimates by $1.51, with revenue also up 8.4% year-over-year.
• Currently, 92.38% of Humana's stock is owned by institutional investors, indicating strong analyst interest and involvement.

Bellwether Advisors LLC bought a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 8,732 shares of the insurance provider's stock, valued at approximately $2,310,000.

A number of other hedge funds have also modified their holdings of the company. Dodge & Cox lifted its holdings in Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the last quarter. Pzena Investment Management LLC increased its position in Humana by 6.1% during the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after purchasing an additional 219,541 shares during the period. Geode Capital Management LLC increased its position in Humana by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider's stock worth $729,658,000 after purchasing an additional 63,562 shares during the period. Invesco Ltd. increased its position in Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider's stock worth $608,348,000 after purchasing an additional 550,692 shares during the period. Finally, Norges Bank acquired a new position in Humana during the 4th quarter worth approximately $416,202,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HUM shares. Guggenheim started coverage on Humana in a report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target on the stock. Wells Fargo & Company set a $348.00 price target on Humana in a report on Friday, July 18th. Piper Sandler lowered their price target on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a report on Thursday. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a report on Thursday, May 1st. Finally, Robert W. Baird lowered their price target on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Sixteen investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $281.62.

Humana Stock Down 4.1%

NYSE HUM traded down $10.71 during trading hours on Thursday, hitting $250.76. The company had a trading volume of 1,767,713 shares, compared to its average volume of 1,741,394. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The company has a market capitalization of $30.26 billion, a price-to-earnings ratio of 17.75, a P/E/G ratio of 1.59 and a beta of 0.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The firm's 50 day moving average is $234.17 and its 200 day moving average is $255.74.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.42% and a return on equity of 14.47%. The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the prior year, the company posted $6.96 earnings per share. The firm's revenue for the quarter was up 9.6% on a year-over-year basis. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.